Skip Navigation


Annals of Oncology Advance Access originally published online on January 27, 2005
Annals of Oncology 2005 16(3):425-429; doi:10.1093/annonc/mdi092
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/3/425    most recent
mdi092v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Delaunoit, T.
Right arrow Articles by Findlay, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delaunoit, T.
Right arrow Articles by Findlay, B. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741

T. Delaunoit1, S. R. Alberts1, D. J. Sargent2,*, E. Green2, R. M. Goldberg3, J. Krook4, C. Fuchs5, R. K. Ramanathan6, S. K. Williamson7, R. F. Morton8 and B. P. Findlay9

1 Department of Oncology, 2 Cancer Center Statistics, Mayo Clinic, Rochester, MN; 3 Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC; 4 Duluth Clinic, Duluth, MN; 5 Dana-Farber Cancer Institute, Boston, MA; 6 University of Pittsburgh Cancer Institute, Pittsburgh, PA; 7 University of Kansas Medical Center, Kansas City, KS; 8 Iowa Oncology Research Association CCOP, Des Moines, IA, USA; 9 National Cancer Institute of Canada, St Catharines, Canada

* Correspondence to: Dr. D. J. Sargent, Cancer Center Statistics, Mayo Clinic, Kahler 1A, 200 First St Southwest, Rochester, MN 55905, USA. Tel: +1-507-284-5380; Fax: +1-507-266-2477; Email: sargent.daniel{at}mayo.edu

Background: Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC). Here we identify and describe patients treated on Intergroup study N9741 who initially had inoperable MCRC, but who obtained sufficient chemotherapeutic benefit to allow removal of their metastatic disease.

Patients and methods: Patient research records in study arms (A) irinotecan/5-FU/leucovorin (LV) (IFL, n=264), (F) oxaliplatin/5-FU/LV (FOLFOX4, n=267) and (G) oxaliplatin/irinotecan (IROX, n=265) were reviewed. TTP and median OS were calculated.

Results: Twenty-four (3.3%) of 795 randomized patients underwent curative metastatic disease resection [hepatectomy, 16; radiofrequency-ablation (RFA), six; lung resection, two]. Twenty-two out of 24 (92%) resected patients received an oxaliplatin-based regimen (FOLFOX4, 11; IROX, 11). Seven patients (29.2%) remain disease-free; relapses occurred mainly in the resected organ. Median OS in resected patients is 42.4 months, and median TTP is 18.4 months. All six patients treated with RFA have recurred. Four out of five (80%) patients who received chemotherapy following resection are disease-free.

Conclusions: Resection of metastatic disease after chemotherapy is possible in a small but important subset of patients with MCRC, particularly after receiving an oxaliplatin-based chemotherapy regimen, with encouraging OS and TTP observed in these highly selected patients.

Key words: chemotherapy, colorectal cancer, resection


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, E. Green, H. K. Sanoff, H. McLeod, and J. Buckner
NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial
Oncologist, October 1, 2009; 14(10): 970 - 978.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang
A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer
Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp114v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. K. Sanoff, D. J. Sargent, E. M. Green, H. L. McLeod, and R. M. Goldberg
Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial
J. Clin. Oncol., September 1, 2009; 27(25): 4109 - 4115.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kopetz, G. J. Chang, M. J. Overman, C. Eng, D. J. Sargent, D. W. Larson, A. Grothey, J.-N. Vauthey, D. M. Nagorney, and R. R. McWilliams
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
J. Clin. Oncol., August 1, 2009; 27(22): 3677 - 3683.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. O'Connell, M. E. Campbell, R. M. Goldberg, A. Grothey, J.-F. Seitz, J. K. Benedetti, T. Andre, D. G. Haller, and D. J. Sargent
Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
J. Clin. Oncol., May 10, 2008; 26(14): 2336 - 2341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Adam, T. Aloia, F. Levi, D. A. Wicherts, R. J. de Haas, B. Paule, M.-P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, et al.
Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy
J. Clin. Oncol., October 10, 2007; 25(29): 4593 - 4602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy, J. E. Krook, E. M. Green, D. J. Sargent, T. Delaunoit, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, et al.
Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741
J. Clin. Oncol., August 10, 2007; 25(23): 3469 - 3474.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
S. A. Gulec and Y. Fong
Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases
Arch Surg, July 1, 2007; 142(7): 675 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L Rubbia-Brandt, E Giostra, C Brezault, A. Roth, A Andres, V Audard, P Sartoretti, B Dousset, P. Majno, O Soubrane, et al.
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
Ann. Onc., February 1, 2007; 18(2): 299 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. P. Ryan
Nonsurgical Approaches to Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 999 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Goldberg, D. Niedzwiecki, M. Bertagnolli, A. W. Blackstock, J. E. Tepper, and R. J. Mayer
Cancer and leukemia group B gastrointestinal cancer committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3589s - 3595s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Bilchik, G. Poston, S. A. Curley, S. Strasberg, L. Saltz, R. Adam, B. Nordlinger, P. Rougier, and L. S. Rosen
Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note
J. Clin. Oncol., December 20, 2005; 23(36): 9073 - 9078.
[Full Text] [PDF]

Home page
 JCOHome page
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066.
[Full Text] [PDF]

Home page
 JCOHome page
H. Kelly and R. M. Goldberg
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
J. Clin. Oncol., July 10, 2005; 23(20): 4553 - 4560.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.